Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025 Pharmaceutical Investing
Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results Pharmaceutical Investing
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2025 and Provides Business Update Pharmaceutical Investing
ABVC BioPharma, Inc. Reports 103% Year-Over-Year Asset Growth and Secures $350K in Post-Quarter Licensing Revenue in Q2 2025 Pharmaceutical Investing
BriaCell Selected for MSK's 2025 Therapeutics Accelerator Program for Bria-OTS+ for Cancer Biotech Investing
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST-Modifier Gene Therapy for Stargardt Disease Pharmaceutical Investing
Medexus Announces Fiscal Q1 2026 Results, Including Positive Results from US Launch of GRAFAPEX for Injection Pharmaceutical Investing
